GSK GSK plc

   By Ian Walker 
 

LONDON--GlaxoSmithKline PLC (GSK.LN) on Wednesday said it has filed regulatory submissions in the U.S. and Europe seeking approval for mepolizumab as a maintenance treatment for patients with severe eosinophilic asthma.

The pharmaceutical giant also said regulatory filings are planned in other countries during the rest of 2014 and 2015. Mepolizumab is not currently approved for use anywhere in the world, it added.

-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

Subscribe to WSJ: http://online.wsj.com?mod=djnwires